Cantor’s 2022 brain week continues as Managing Director and Senior Biotech Analyst, Charles C. Duncan, PhD, hosted Intra-Cellular Therapies for a fireside chat.

• The discussion with senior management focused on CAPLYTA’s revenue growth and TAM expansion opportunities beyond currently approved indications to treat schizophrenia and BPD 1&2 in adults.

• Charles believes CAPYLTA’s differentiated efficacy and safety profile will continue to accelerate prescription growth and possibly result in increased treatment adherence compared to other medications.

• Furthermore, Charles is intrigued with CAPLYTA’s clinical evaluation in MDD/BPD with mixed features and as a MDD adjunctive treatment, both sizable unmet needs with highly burdensome symptoms.

• Key upcoming catalysts include topline results of Study 403 for MDD/BPD with mixed features in 1Q23, as well as quarterly sales updates.

Our second Neuro-Innovator company interaction this week is “in the books.” Stay tuned for more updates from Cantor’s Neurology & Psychiatry conference in San Francisco, including two keynote presentations and 11 panels with ~40 companies this week.

#Cantorconferenceseries #Neurology #Psychiatry #Cantorfitzgerald